JP2011509297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509297A5 JP2011509297A5 JP2010542297A JP2010542297A JP2011509297A5 JP 2011509297 A5 JP2011509297 A5 JP 2011509297A5 JP 2010542297 A JP2010542297 A JP 2010542297A JP 2010542297 A JP2010542297 A JP 2010542297A JP 2011509297 A5 JP2011509297 A5 JP 2011509297A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- pain
- formula
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 5
- 230000036407 pain Effects 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/971,829 US7902247B2 (en) | 2008-01-09 | 2008-01-09 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| PCT/US2009/030074 WO2009089132A1 (en) | 2008-01-09 | 2009-01-05 | Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509297A JP2011509297A (ja) | 2011-03-24 |
| JP2011509297A5 true JP2011509297A5 (https=) | 2012-02-23 |
Family
ID=40457040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542297A Pending JP2011509297A (ja) | 2008-01-09 | 2009-01-05 | α２Ｂおよび／またはα２Ｃアドレナリン受容体のサブタイプ選択的モジュレーターとしての置換アリール−２−フェニルエチル−１Ｈ−イミダゾール化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7902247B2 (https=) |
| EP (1) | EP2240453A1 (https=) |
| JP (1) | JP2011509297A (https=) |
| AU (1) | AU2009204358A1 (https=) |
| BR (1) | BRPI0907613A2 (https=) |
| CA (1) | CA2711464A1 (https=) |
| WO (1) | WO2009089132A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002226225B2 (en) * | 2001-01-18 | 2008-03-20 | Dermavant Sciences GmbH | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| BRPI0812385A2 (pt) * | 2007-05-23 | 2019-09-24 | Allergan Inc | lactamas cíclicas para o tratamento de glaucoma ou pressão intraocular elevada |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
| US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| HRP20141047T1 (hr) | 2008-08-01 | 2015-01-02 | Eye Therapies Llc | Pripravci za sužavanje krvnih žila i metode njihove uporabe |
| US12246013B2 (en) | 2008-08-01 | 2025-03-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| JP2012517433A (ja) * | 2009-02-06 | 2012-08-02 | アラーガン インコーポレイテッド | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物 |
| US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
| US20110152271A1 (en) * | 2009-12-17 | 2011-06-23 | Gerald Horn | Compositions and methods for ophthalmic delivery of nasal decongestants |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| US9071616B2 (en) | 2010-11-18 | 2015-06-30 | Microsoft Technology Licensing, Llc | Securing partner-enabled web service |
| US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| KR101537204B1 (ko) | 2012-05-08 | 2015-07-22 | 론자 아게 (론자 엘티디.) | 2-(2,3-디메틸페닐)-1-프로파날의 제조 방법 |
| US9045433B2 (en) * | 2012-05-08 | 2015-06-02 | Lonza Ltd. | Method for preparation of medetomidine |
| WO2012172119A2 (en) * | 2012-05-08 | 2012-12-20 | Lonza Ltd | Method for the preparation of medetomidine |
| CA2866441C (en) | 2012-06-28 | 2017-01-17 | Lonza Ltd. | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone |
| WO2013011157A1 (en) | 2012-06-28 | 2013-01-24 | Lonza Ltd | Method for preparation of medetomidine with chloroacetone |
| US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
| JP2019517524A (ja) * | 2016-06-02 | 2019-06-24 | パーデュー ファーマ エルピー | 疼痛治療のための微量アミン関連受容体１アゴニスト及び部分アゴニスト |
| WO2025171183A1 (en) * | 2024-02-06 | 2025-08-14 | Aglaeapharma Inc. | Imidazole containing compounds, derivatives therefore, and uses thereof |
| WO2025231265A1 (en) * | 2024-05-01 | 2025-11-06 | Alpherabio Llc | Combination with alpha-2 adrenergic receptor agonist |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU795462A3 (ru) | 1975-03-14 | 1981-01-07 | Эдьт Дьедьесерведьесети Дьяр (Фирма) | Способ получени тиокарбамидныхпРОизВОдНыХ |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPH032168A (ja) | 1989-03-30 | 1991-01-08 | Farmos Yhtymae Oy | アロマターゼ阻害活性を有する新規な４（５）―イミダゾール |
| US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
| GB9125924D0 (en) * | 1991-06-18 | 1992-02-05 | Orion Yhtymae Oy | Stereoisomers of an imidazole derivative |
| GB9310965D0 (en) * | 1993-05-27 | 1993-07-14 | Ucb Sa | 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| PL341009A1 (en) | 1997-12-04 | 2001-03-12 | Allergan Sales | Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors |
| TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| WO2006036507A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| RU2008130448A (ru) | 2006-01-27 | 2010-03-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Применение производных 4-имидазола для расстройств цнс |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| AU2009205539B2 (en) * | 2008-01-18 | 2013-12-05 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US8063231B2 (en) * | 2008-06-09 | 2011-11-22 | Allergan, Inc. | Methods of treating alpha adrenergic mediated conditions |
| ES2672777T3 (es) * | 2008-06-09 | 2018-06-18 | Allergan, Inc. | Métodos de tratamiento de estados con mediación alfa-adrenérgica |
-
2008
- 2008-01-09 US US11/971,829 patent/US7902247B2/en active Active
-
2009
- 2009-01-05 EP EP09700891A patent/EP2240453A1/en not_active Withdrawn
- 2009-01-05 AU AU2009204358A patent/AU2009204358A1/en not_active Abandoned
- 2009-01-05 CA CA2711464A patent/CA2711464A1/en not_active Abandoned
- 2009-01-05 JP JP2010542297A patent/JP2011509297A/ja active Pending
- 2009-01-05 BR BRPI0907613-1A patent/BRPI0907613A2/pt not_active IP Right Cessation
- 2009-01-05 WO PCT/US2009/030074 patent/WO2009089132A1/en not_active Ceased
-
2010
- 2010-12-13 US US12/966,560 patent/US8735438B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509297A5 (https=) | ||
| JP2011522774A5 (https=) | ||
| JP2014520072A5 (https=) | ||
| MX2015001500A (es) | Compuestos antidiabeticos triciclicos. | |
| JP2015501783A5 (https=) | ||
| JP2007516941A5 (https=) | ||
| JP2005521671A5 (https=) | ||
| JP2015518491A5 (https=) | ||
| JP2014502982A5 (https=) | ||
| JP2008526888A5 (https=) | ||
| CA2702047A1 (en) | Substituted biphenyl gpr40 modulators | |
| JP2020502092A5 (https=) | ||
| JP2017524005A5 (https=) | ||
| JP2015531764A5 (https=) | ||
| CO6531470A2 (es) | Derivados benzamida sustituidos | |
| JP2014510097A5 (https=) | ||
| JP2015503610A5 (https=) | ||
| TW201542553A (zh) | 氮雜吡啶酮化合物及其用途 | |
| JP2013536833A5 (https=) | ||
| RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
| JP2016514117A5 (https=) | ||
| JP2015508092A5 (https=) | ||
| JP2009525330A5 (https=) | ||
| JP2013507371A5 (https=) | ||
| JP2013523846A5 (https=) |